Ultime notizie per VICI Properties (NYSE:VICI) Azioni

VICI PROPERTIES INC

VICI Properties

VICI Props

VICI Properties Inc is a real estate investment trust based in the United States. It engaged in the business of owning and acquiring gaming, hospitality, wellness, entertainment and leisure destinations, subject to long-term triple net leases. It own nearly 93 experiential assets across a geographically portfolio consisting of nearly 54 gaming properties and nearly 39 other experiential properties across the United States and Canada, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas.

VICI Properties Inc

Vicinity Centres

Vicinity Motor Corp

Barclays analyst Theresa Chen maintains Kinetik Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNTK#NYSE">KNTK</a>) with a Equal-Weight and lowers the price target from $49 to $43.

News

Price Target

Analyst Ratings

KNTK

Barclays Maintains Equal-Weight on Kinetik Holdings, Lowers Price Target to $43

Keybanc analyst Scott Schoenhaus maintains Hinge Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNGE#NYSE">HNGE</a>) with a Overweight and raises the price target from $45 to $60.

HNGE

Keybanc Maintains Overweight on Hinge Health, Raises Price Target to $60

WIIM

VSEE

VSee Health shares are trading higher after the company announced the launch of its new AI doctor notes.

Keybanc analyst Aleksey Yefremov maintains FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Overweight and raises the price target from $53 to $61.

Keybanc Maintains Overweight on FMC, Raises Price Target to $61

Barclays analyst Saket Kalia maintains Hinge Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNGE#NYSE">HNGE</a>) with a Overweight and raises the price target from $43 to $51.

Barclays Maintains Overweight on Hinge Health, Raises Price Target to $51

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Baird analyst Joe Vruwink upgraded the rating for nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) from Neutral to Outperform and raised the price target from $30 to $38. Ncino shares closed at $28.82 on Friday. <a href="https://www.benzinga.com/quote/ncno/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Jeff Cantwell upgraded Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) from Neutral to Buy and maintained the price target of $616. Mastercard shares closed at $550.18 on Friday. <a href="https://www.benzinga.com/quote/ma/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Robert Moskow upgraded the rating for WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) from Sell to Hold and raised the price target from $14 to $23. WK Kellogg shares closed at $22.89 on Friday. <a href="https://www.benzinga.com/quote/klg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Joseph Spak upgraded Visteon Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) from Neutral to Buy and raised the price target from $85 to $142. Visteon shares closed at $110.73 on Friday. <a href="https://www.benzinga.com/quote/vc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Ralph Schackart upgraded the rating for Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) from Market Perform to Outperform. Stitch Fix shares closed at $3.94 on Friday. <a href="https://www.benzinga.com/quote/sfix/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14082603/image-155-1024x582.png" alt="" class="wp-image-983887" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14082603/image-155-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14082603/image-155-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14082603/image-155-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14082603/image-155.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46388321/top-3-health-care-stocks-that-could-blast-off-in-july">Top 3 Health Care Stocks That Could Blast Off In July</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

NCNO

SFIX

This Mastercard Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

DGNX

Diginex shares are trading lower after the company reported FY25 financial results.

Keybanc analyst Aleksey Yefremov maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Overweight and raises the price target from $28 to $29.

Keybanc Maintains Overweight on Element Solutions, Raises Price Target to $29

Keybanc analyst Aleksey Yefremov maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Overweight and lowers the price target from $117 to $112.

ENTG

Keybanc Maintains Overweight on Entegris, Lowers Price Target to $112

DEFT

Defi Technologies shares are trading higher after the company provided Bitcoin assets under management updates for its subsidiary, Valour.

Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)&nbsp;has agreed to combine its Biosciences &amp; Diagnostic Solutions business with Waters Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>).
The agreement is structured as a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion. The transaction is expected to close around the end of the first quarter of calendar year 2026.
<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Biosciences segment</a> offers immunology and cancer research solutions and related clinical diagnostics, including flow cytometry instruments, reagents, and multiomics tools.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/05/45179007/becton-dickinson-vitals-drop-analysts-have-been-wrong-on-this-med-tech-stock-for-years" target="_blank" rel="noreferrer noopener">Becton Dickinson Vitals Drop: Analysts &#8216;Have Been Wrong&#8217; On This Med Tech Stock For Years</a>
Diagnostic Solutions offers microbiology and infectious disease diagnostics, including molecular diagnostics, cervical cancer screening, microbiology automation, and point-of-care offerings.
For calendar year 2025, BD&#8217;s Biosciences &amp; Diagnostic Solutions business is expected to generate revenue of approximately&nbsp;$3.4 billion&nbsp;and adjusted EBITDA of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46387499/waters-and-bds-biosciences-diagnostic-solutions-business-to-combine-creating-a-life-science-and-di" rel="noreferrer noopener">approximately&nbsp;$925 million</a>.
<h2 class="wp-block-heading">Financial Benefits</h2>
The transaction is expected to create approximately&nbsp;$200 million&nbsp;of cost synergies by year three post-closing, and approximately&nbsp;$290 million&nbsp;of revenue synergies by year five, resulting in approximately&nbsp;$345 million&nbsp;of annualized EBITDA synergies by 2030.
Cost synergies are expected to be driven primarily by manufacturing, supply chain, and SG&amp;A optimization while maintaining a strong commitment to R&amp;D and commercial investments.
Revenue synergies are expected from commercial excellence, accelerating expansion into high-growth adjacencies, and realizing cross-selling opportunities.
The combined company is expected to generate pro forma revenue of approximately&nbsp;$6.5 billion&nbsp;and approximately&nbsp;$2.0 billion&nbsp;in pro forma adjusted EBITDA for calendar year 2025.
On a pro forma basis, the combination is expected to deliver mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth on an annualized basis between 2025 and 2030.
By 2030, the pro forma combined company is expected to have an industry-leading financial outlook with approximately&nbsp;$9 billion&nbsp;in revenue,&nbsp;$3.3 billion&nbsp;in adjusted EBITDA, and an adjusted operating margin of 32%.
The transaction is expected to be accretive to adjusted EPS in the first year post-closing.
Commenting on the transaction, Flemming Ornskov, Chairman, Waters, said, &#8220;This transaction marks a pivotal milestone in Waters&#8217; transformation journey as we embark on a new chapter of growth and value creation. As the Board of Directors evaluated this opportunity throughout the process, it became evident that combining with BD&#8217;s Biosciences &amp; Diagnostic Solutions business is an excellent strategic fit with complementary strengths. We are confident that this combination will accelerate our strategy in multiple high-growth markets and deliver substantial near- and long-term value to our shareholders.&#8221;
BD&#8217;s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters shareholders are expected to own approximately 60.8%. BD will also receive a cash distribution of approximately $4 billion before completion of the combination.
Waters is expected to assume approximately&nbsp;$4 billion&nbsp;of incremental debt, resulting in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing.
Price Action: WAT stock was down 5.07% at $335, and BDX stock was down 0.84% at $174.50 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46386582/elon-musk-wants-tesla-to-invest-in-xai-but-its-up-to-shareholders-this-analyst-says-grok-is-worth-the-bet" target="_blank" rel="noreferrer noopener">Elon Musk Wants Tesla To Invest In xAI, But It&#8217;s Up To Shareholders: This Analyst Says Grok Is Worth The Bet</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

Movers

General

Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Merger

VBTX

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Keybanc analyst Scott Schoenhaus maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Overweight and lowers the price target from $106 to $93.

Keybanc Maintains Overweight on Eastman Chemical, Lowers Price Target to $93

Barclays analyst Saket Kalia maintains Gen Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) with a Equal-Weight and raises the price target from $30 to $32.

Barclays Maintains Equal-Weight on Gen Digital, Raises Price Target to $32

SQNS

Sequans shares are trading higher after the company announced it bought 683 more Bitcoins and provided updates on its total holdings.

Keybanc analyst Scott Schoenhaus maintains Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a Overweight and raises the price target from $65 to $70.

DOCS

Keybanc Maintains Overweight on Doximity, Raises Price Target to $70

NCino shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $30 to $38.

Keybanc analyst Aleksey Yefremov maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Overweight and raises the price target from $85 to $87.

Keybanc Maintains Overweight on DuPont de Nemours, Raises Price Target to $87

Barclays analyst Saket Kalia maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Equal-Weight and raises the price target from $103 to $110.

FTNT

Barclays Maintains Equal-Weight on Fortinet, Raises Price Target to $110

CRWD

CrowdStrike Holdings shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight.

Press Releases

VICI Properties Inc. Announces Fourth Quarter and Full Year 2024 Results

PENN Entertainment, Inc. Reports Fourth Quarter Results

VICI Properties Inc. Declares Regular Quarterly Dividend

VICI Properties Announces Pricing of Public Offering of $1.3 Billion of Senior Unsecured Notes

VICI Properties Inc. Announces Release Date for First Quarter 2025 Results

VICI Properties Announces Closing of $1.3 Billion Senior Unsecured Notes Offering

Comments

VICI Properties

Notizie

Ultime notizie per VICI Properties (NYSE:VICI) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO